The Conversation
International · 23 mins ago
✦ 75◉ Centre
HIV in South Africa: why rolling out a groundbreaking new shot will miss a critical group of men
75Quality
0Ratings
0Comments
AI Analysis
Quality 75/100
Partisan intensity 35/100
ObjectivePartisan
◉ Centre ✓ Fair headline
South Africa has received shipments of Lenacapavir, a long-acting HIV prevention injection, with rollout expected in June 2026 prioritising high-risk groups, but the headline suggests a critical population may be excluded from initial distribution plans.
HIV in South Africa: why rolling out a groundbreaking new shot will miss a critical group of men
The first shipment of Lenacapavir, a long-acting injectable that prevents HIV with two shots a year, arrived in South Africa from the United States in early April 2026. Clinical trials showed close to 100% efficacy. The rollout, expected to begin in June 2026, prioritises adolescent girls and young women, pregnant and breastfeeding women, transgender people, sex workers, men who have sex with men, and people who inject drugs.
These are the right populations to start with. But one group repeatedl
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!